Ignite Creation Date:
2024-05-06 @ 2:20 AM
Last Modification Date:
2024-10-26 @ 11:17 AM
Study NCT ID:
NCT02027779
Status:
UNKNOWN
Last Update Posted:
2014-01-06
First Post:
2014-01-02
Brief Title:
Safety and Efficacy Extension Study of GreenGene F in Previously Treated Patients Diagnosed With Severe Hemophilia A
Sponsor:
Green Cross Corporation
Organization:
GC Biopharma Corp
Study Overview
Official Title:
An Open Label Safety and Efficacy Extension Study of GreenGene F in Previously Treated Patients Diagnosed With Severe Hemophilia A
Status:
UNKNOWN
Status Verified Date:
2014-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study primarily will address the safety and secondarily will assess efficacy of GreenGene F in subjects with severe hemophilia A previously treated 50 exposure days with a GreenGene F and without presence inhibitor to FVIII Factor VIII
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None